Viking Therapeutics’ (Nasdaq: VKTX) 40% stock crash this week revealed a fundamental problem plaguing the GLP-1 driven obesity movement: achieving meaningful weight loss while balancing tolerability to keep patients on these drugs long enough to improve their potential heart, diabetes, liver and other serious metabolic conditions. In developing its oral tablet format of VK2735, Viking essentially required a daily dose of 60-120mg to reach attractive weight loss (10-13% at 13 weeks), but this came with 28-38% of patients quitting treatment within just 13 weeks due to side effects.
This setback highlights why the oral peptide delivery market – potentially worth billions – remains largely unconquered despite massive pharmaceutical investment. The challenge isn’t just finding effective compounds; it’s developing oral delivery technology sophisticated enough to make them work at reasonable doses.
Enter Entera Bio (Nasdaq: ENTX), an $86 million biotech that has spent over a decade optimizing its proprietary oral peptide technology and platforms. N-Tab™ delivers a disruptive solution to oral peptide development and each of Entera’s pipeline candidates is customized to optimize patient outcomes. In comparison, even after the massive 40% drop, Viking still trades at a $2.8 billion market cap.
Entera focuses on transforming injectable peptide therapies into convenient daily tablets through its proprietary N-Tab™ platform. Entera’s oral peptide platform houses candidates targeting obesity/improvement of metabolic conditions, osteoporosis, and rare disorders such as hypoparathyroidism.
Why Entera’s Approach May Succeed Where Others Failed
For its obesity and metabolic program, Entera’s collaboration with OPKO Health (Nasdaq: OPK) has created a unique combination of proven compound, advanced platform, and potential for optimized dosing that addresses the core challenges Viking encountered.
Different API with Proven Human Efficacy: Entera’s oral obesity program combines OPKO’s proprietary long-acting oxyntomodulin analog (OPK-88006) with Entera’s N-Tab™ technology. OPKO previously demonstrated significant weight loss and cardioprotective effects in 420 obese and diabetic patients using weekly injections. At the June 2024 Endocrine Society meeting, Entera reported that oral OXM achieved target plasma concentrations with duration consistent with semaglutide (Rybelsus®), plus statistically significant glucose reduction in preclinical studies. IND filing expected early 2026.
Platform Technology is Everything: Viking’s crude approach required significant dosages with high dropout rates. Entera’s N-Tab™ platform uses sophisticated excipients tailored to each peptide, achieving optimized bioavailability in patient-friendly tablets.
PK Data Supports Low-Dose Efficacy: Entera’s IND-enabling PK studies demonstrated the potential for semaglutide (Rybelsus) – equivalent coverage at 25mg daily—5x lower than Viking’s 120mg strategy. This has huge implications for safety and tolerability – not to mention cost and patient access. This also further validates Entera’s N-Tab™ platform superiority.
The Valuation Disconnect – Multiple Billion-Dollar Markets in Play
The market opportunity in oral delivery has attracted serious pharmaceutical investment. Novo Nordisk paid $1.8 billion for Emisphere’s oral absorption technology (used in Rybelsus), while Merck committed up to $493 million for multiple early-stage oral peptide platform access.
Entera’s platform approach creates multiple shots on goal to transform medical markets. Their lead program, EB613, is advancing toward Phase 3 as the first potential oral peptide treatment for osteoporosis, addressing over 200 million women globally who currently face only injectable options. Entera just got a big win with FDA enabling the company to pursue its registrational study using a BMD endpoint in a single placebo controlled study—unprecedented to date and speaks to the strength of the program. In contrast to the obesity space, EB613 is first in class and the only oral peptide targeting the estimated $12 billion osteoporosis market.
Additionally, EB612, Entera’s program for hypoparathyroidism would be the first oral PTH hormone replacement for 60,000-115,000 U.S. patients, potentially disrupting Ascendis Pharma’s dominant position with recently launched Yorvipath which requires daily injections (Nasdaq: ASND).
Yet Entera trades at just $86 million – a fraction of Viking’s $2.8 billion market, and that’s after Viking’s 40% dive. Notably, while Entera’s stock ascended 400% in 2024, it seems to remain under the radar. The one Wall Street analyst covering the Company has issued a buy rating and a $10 price target, implying 400%+ potential upside. With the recent endpoint win for EB613 and plans to move oral OXM to the clinical phase next year, it appears the thesis may be starting to play out.
For investors seeking exposure to the next breakthrough in biotechnology, the answer may not lie in the companies making headlines, but in those quietly solving the fundamental challenges others can’t crack, before they hit the headlines.
Recent News Highlights from Entera:
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates
Disclaimer & Disclosure: This content is a form of paid promotional content and advertising. Wall Street Wire has received cash compensation from Entera Bio Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures. We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. This article should not be considered an official communication by the issuer.
